Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 204-340-2
CAS number: 119-64-2
Area under the curve (AUC) (µg*h/mL)
15 mg/kg bw
0.78 mg/L (36 min)
0.62 mg/l (34 min)
0.76 mg/L (30 min)
1.35 mg/l (29 min)
50 mg/kg bw
2.57 mg/L (99 min)
1.04 mg/l (90 min)
3.46 mg/L (43 min)
3.14 mg/l (84 min)
150 mg/kg bw
19.01 mg/L (30 min)
5.54 mg/l (31 min)
9.64 mg/L (30 min)
12.02 mg/l (88 min)
Maximum concentrations of first sampling males > females
Maximum concentrations of second sampling females > males
=> The tetrahydronaphthalene blood concentration maximum was reached
approximately 30 minutes after administration of the highest dose.
AUC of second sampling always lower with males, higher with females as
compared to first sampling
=> The AUC of the high dose groups is more than proportional higher than that
of the lower dose groups indicating that elimination may be saturated at this dose level. An accumulation of test substance after
repeated oral administration of up to 150 mg/kg body weight was, however, not observed.
FIRST ORDER HALF LIVES OF ELIMINATION (1 compartment model)
high dose, male: 82.2 min
reversal, male: 99.5 min
high dose, female: 80.8 min
reversal, female: 85.0 min
FIRST ORDER HALF LIFE OF ELIMINATION (2 compartments model)
ca. 4.7 hours (males)
=> After 23 hrs, only traces of test substance were detectable in the blood. The elimination half life was determined in the range
of 30 to 100 minutes. In the low and mid dose groups, elimination was almost finished after 6 hours.
OTHER / GENERAL OBSERVATIONS:
Dark coloured urine was observed in all treated animals.
Tox. behaviour: see chapter 5.4
The present study describes the kinetics of
tetrahydronaphthalene in male and female rats (five
animals per dose per sex) at three dose levels (15, 50,
and 150 mg/kg daily). Plasma concentration measurements
were performed in the course of a subacute toxicity study
of 28 days duration in an enriched study design. Two blood
samples per animal were taken at different time points
after application at day 1 and 16 (150 mg/kg daily) and at
day 3 and 18 (15 and 50 mg/kg daily), respectively.
Tetrahydronaphthalene was assayed by gas
chromatography-mass spectrometry (GC-MS) after extraction.
The data of plasma concentration time were analysed using
non-linear mixed effects modelling as implemented in
NONMEM. The structural model with the best fit employed
one compartment kinetics with instantaneous drug input.
Interindividual variability in both k and V was found to
be very small [k, 0.201 h(-1), 0.013; V, 16.19 (kg), 1.77;
population mean and SE]. No unequivocal evidence of dose
dependence could be found. The kinetic parameter with the
highest extent of variability was the extent of
bioavailability which showed an coefficient of variation
(CV) of 96%. Both gender and dose had no influence on the
variability. The results of this study indicate that
tetrahydronaphthalene is rapidly absorbed from the
gastrointestinal tract and also rapidly excreted. Upon
repeated application by gavage resorption was delayed at
the highest dose level. There appears to be no induction
of elimination upon repeated dosing. At higher dose level
elimination is apparently saturated.
There was no accumulation upon repeated oral
application of tetrahydronaphthalene up to 150 mg/kg bw.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
Welcome to the ECHA website. This site is not fully supported in Internet Explorer 7 (and earlier versions). Please upgrade your Internet Explorer to a newer version.
Do not show this message again